Apollon Formularies (AQSE:APOL) EPS (Diluted) : £-0.00 (TTM As of Jun. 2023)

View and export this data going back to . Start your Free Trial

What is Apollon Formularies EPS (Diluted)?

Apollon Formularies's Earnings per Share (Diluted) for the six months ended in Jun. 2023 was £-0.00. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.00.

Apollon Formularies's EPS (Basic) for the six months ended in Jun. 2023 was £-0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.00.

Apollon Formularies's EPS without NRI for the six months ended in Jun. 2023 was £-0.00. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.00.

During the past 3 years, the average EPS without NRIGrowth Rate was 47.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 11 years, Apollon Formularies's highest 3-Year average EPS without NRI Growth Rate was 51.50% per year. The lowest was -63.60% per year. And the median was 22.40% per year.

Apollon Formularies EPS (Diluted) Historical Data

The historical data trend for Apollon Formularies's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollon Formularies EPS (Diluted) Chart

Apollon Formularies Annual Data

Trend

Jun10

Jun11

Dec12

Dec13

Dec14

Dec17

Dec18

Dec19

Dec20

Dec21

EPS (Diluted)

Get a 7-Day Free Trial

-0.02

-0.09

-0.01

Apollon Formularies Semi-Annual Data
	Jun11	Jun12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec17	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Jun23
EPS (Diluted)	Get a 7-Day Free Trial											-	-0.01	-	-	-

Competitive Comparison of Apollon Formularies's EPS (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Apollon Formularies's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Apollon Formularies's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Apollon Formularies's PE Ratio distribution charts can be found below:

* The bar in red indicates where Apollon Formularies's PE Ratio falls into.

Apollon Formularies EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Apollon Formularies's Diluted EPS for the fiscal year that ended in Dec. 2021 is calculated as

Diluted EPS (A: Dec. 2021 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-2.531	-	0)	/	548.103
	=	-0.00

Apollon Formularies's Diluted EPS for the quarter that ended in Jun. 2023 is calculated as

Diluted EPS (Q: Jun. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-0.764	-	0)	/	771.191
	=	-0.00

EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.00

Apollon Formularies (AQSE:APOL) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Apollon Formularies EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Apollon Formularies's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Apollon Formularies (AQSE:APOL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apollon Formularies PLC (AQSE:APOL) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

6 Hope Street, Quayside House, Castletown, IMN, IM9 1AS

Website

https://www.apollon.org.uk

Apollon Formularies PLC is a London, England and Jamaican based medical cannabis pharmaceutical company specialising in research and treatment of patients with cancer and chronic pain. It is engaged in investing by seeking to acquire a direct and/or indirect interest in projects and assets in the agriculture and logistics sectors and the medicinal cannabis sector. The company focus on opportunities in Africa and Europe. It has created proprietary hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products.